Though these trials are encouraging, limitations are noticeable in the form of methodological issues that restrict the interpretation of results. In this review, we discuss the methodological pitfalls of high-profile clinical interventional trials for ADPKD which have been published since 2009. Issues ...
Chang, MY, Ong, AC (2012) Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron 120: pp. 25-34 About this Chapter Title Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trials: A Critical Appraisal Book Title Info...
Understanding the frequency of these events, as well as potential contributors (for example, a rapidly increasing rate of cyst or renal growth), provides critical information for establishing inclusion criteria for enrollment into randomized clinical trials in ADPKD as well as considerations for ...
University of Groningen Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease Irazabal, 来自 Semantic Scholar 喜欢 0 阅读量: 6 作者: M Irazabal,J Blais,R Perrone,R Gansevoort,A Chapman,O Devuyst,E Higashihara,P Harris,W Zhou,J Ouyang 展开 ...
; results of randomized controlled trials (RCTs) of tolvaptan, somatostatin analogues, levels of blood pressure (BP) targets, renin–angiotensin blockade, and other potential treatments for ADPKD have been published; and tolvaptan has been approved for the treatment of rapidly progressive ADPKD. ...
Clinical trials are crucial for the advancement of treatment and knowledge within the medical community. Although the ClinicalTrials.gov initiative has res... ME Elkin,X Zhu - 《Network Modeling Analysis in Health Informatics & Bioinformatics》 被引量: 0发表: 2021年 A community-centered approach ...
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol. Dial. Transplant. 2018, 33, 645–652. [Google Scholar] [CrossRef] [PubMed] Audrézet, M.P.; Corbiere, C.; Leb...
ClinicalTrials数据库提供临床试验Daily Caloric Restriction in ADPKD的登记号NCT04907799,试验分期N/A以及申办者University of Colorado, Denver的信息,更过关于临床试验的其他信息查询就在戊戌数据美国临床试验数据库.
- 《Contemporary Clinical Trials》 被引量: 18发表: 2013年 Vascular abnormalities in patients with autosomal dominant polycystic kidney disease--the influence on arteriovenous fistula creation. AIM: Patients with autosomal dominant polycystic kidney (ADPKD) present a number of vascular abnormalities, ...
(RAR) agonist, as a candidate drug for the treatment of autosomal dominant polycystic kidney disease (ADPKD), which is expected to suppress cyst formation and improve kidney function. Rege Nephro began its Phase 2a clinical trials in December 2023. Additionally, through multiple mouse model ...